Risk factor
Strong trading liquidity
Profitability factor
Very low or no dividends
About
BGI Genomics Co., Ltd. operates as an international supplier of genetic testing solutions and sequencing services. The company caters to a broad clientele, encompassing medical and research facilities, as well as other public and private organizations, both within China and across the globe. Its comprehensive service portfolio includes DNA, RNA, and tailored sequencing options. Additionally, it offers a suite of specialized genetic tests such as non-invasive prenatal testing (NIPT), reproductive health screening, and newborn genetic screening, alongside clinical exome sequencing. BGI Genomics also develops clinical and research-focused solutions for the field of oncology. During the COVID-19 pandemic, the firm provided crucial laboratory solutions for the detection and diagnosis of suspected cases, including SARS-CoV-2 IgM and IgG antibody detection kits, and real-time fluorescent RT-PCR kits. Their expertise spans numerous research domains, including but not limited to agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug development. Established in 1999, the company initially operated under the name Shenzhen BGI Medicine Co., Ltd. before officially changing to BGI Genomics Co., Ltd. in 2015. Its corporate headquarters are located in Shenzhen, China.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of 300676.SZ is 51.1 and suggests 26.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to